search
Back to results

Validation of the Hebrew Version of the Montreal Affective Voices.

Primary Purpose

Parkinson's Disease, Depression

Status
Unknown status
Phase
Locations
Israel
Study Type
Observational
Intervention
Sponsored by
Hadassah Medical Organization
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an observational trial for Parkinson's Disease

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Healthy group
  • Parkinson's disease
  • Major depressive disorder
  • All participants will be competent and willing to give written informed consent. Patients over 65 and/or suspected to have a cognitive decline will be tested by the Mini-mental test and will be included in the study only if the score is above 26.

Exclusion Criteria:

  • Non-competent or unable to give written informed consent

Sites / Locations

  • Hadassah Medical Organization,

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Arm Label

healthy control group

Parkinson's disease patients

Major depressive disorder patients

Arm Description

Young (20-49) and Older (50-70) healthy group (n=60)

(n=30).

(n=30).

Outcomes

Primary Outcome Measures

Verifying the results achieved by Belin et al (2008) when using the Hebrew version of the MAV bursts in healthy control groups.

Secondary Outcome Measures

Full Information

First Posted
January 15, 2012
Last Updated
January 22, 2012
Sponsor
Hadassah Medical Organization
search

1. Study Identification

Unique Protocol Identification Number
NCT01512732
Brief Title
Validation of the Hebrew Version of the Montreal Affective Voices.
Study Type
Observational

2. Study Status

Record Verification Date
January 2012
Overall Recruitment Status
Unknown status
Study Start Date
February 2012 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hadassah Medical Organization

4. Oversight

5. Study Description

Brief Summary
Today, no non-verbal auditory stimuli that assess mental processing are available in Israel. The goal of this study is to make available a validated set of auditory stimuli in Israel. We created a computerized Hebrew version of the Montreal Affective Voices (MAV). The MAV is a novel tool for assessing mental processing. The MAV consists of 90 nonverbal affect bursts corresponding to nine different emotions (such as anger, fear, happiness etc.) recorded by ten different actors. The uniqueness of these affective bursts is that they do not contain verbal context, but rather express affective moods using the vowel /a/ (as in "apple"). In this study, the investigators will verify the new Hebrew version of MAV in healthy control groups. Next, the investigators will compare the mental processing ability in young vs. old population, using the MAV test. In addition, the investigators will assess mental processing in two pathologic study groups (Parkinson's disease, major depressive disorder) using the MAV test. The investigators intend to use the MAV tool in future research in Parkinson's disease and depression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson's Disease, Depression

7. Study Design

Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
healthy control group
Arm Description
Young (20-49) and Older (50-70) healthy group (n=60)
Arm Title
Parkinson's disease patients
Arm Description
(n=30).
Arm Title
Major depressive disorder patients
Arm Description
(n=30).
Primary Outcome Measure Information:
Title
Verifying the results achieved by Belin et al (2008) when using the Hebrew version of the MAV bursts in healthy control groups.
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy group Parkinson's disease Major depressive disorder All participants will be competent and willing to give written informed consent. Patients over 65 and/or suspected to have a cognitive decline will be tested by the Mini-mental test and will be included in the study only if the score is above 26. Exclusion Criteria: Non-competent or unable to give written informed consent
Study Population Description
healthy group, Parkinson's disease patients, Major depressive disorder patients.
Sampling Method
Non-Probability Sample
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Renana Eitan, Dr
Phone
972-050-4048165
Email
renanaeitan@gmail.com
Facility Information:
Facility Name
Hadassah Medical Organization,
City
Jerusalem,
Country
Israel
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hadas Lemberg, PhD
Phone
00 972 2 6777572
Email
lhadas@hadassah.org.il
First Name & Middle Initial & Last Name & Degree
Renana Eitan, MD

12. IPD Sharing Statement

Learn more about this trial

Validation of the Hebrew Version of the Montreal Affective Voices.

We'll reach out to this number within 24 hrs